# Narayana Hrudayalaya (NSE: NH) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/NH · Pivot · prices to 22 Oct 2026

Narayana Hrudayalaya (NSE: NH) closed at ₹1,691.90 on 22 Oct 2026, down 2.21% on the day. With a market capitalisation of ₹34,576 Cr, it ranks 244th by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.

At its last close the stock traded at 42.4× trailing earnings, against a return on equity of 17.8% in FY26. Over the past year the share price has fallen 2.8%. Its 52-week range is ₹1,589.00 (2 Apr 2026) to ₹2,093.30 (17 Nov 2025); the last close is 19.2% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹2,684 Cr (+78.0% year on year) and net profit ₹209 Cr (+6.1%), on a consolidated basis. Promoters held 63.27% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹1,691.90 |
| Market cap | ₹34,576 Cr |
| P/E (trailing) | 42.4 |
| ROE | 17.8% (FY26) |
| ROCE | 11.9% (FY26) |
| Debt to equity | 1.07 |
| 52-week high | ₹2,093.30 (17 Nov 2025) |
| 52-week low | ₹1,589.00 (2 Apr 2026) |
| 1-year return | −2.8% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹2,684 Cr | +78.0% | ₹209 Cr | +6.1% | ₹10.20 |
| Q4 FY26 | ₹2,594 Cr | +75.8% | ₹226 Cr | +14.5% | ₹11.02 |
| Q3 FY26 | ₹2,151 Cr | +57.4% | ₹127 Cr | −34.3% | ₹6.24 |
| Q2 FY26 | ₹1,644 Cr | +17.4% | ₹259 Cr | +30.0% | ₹12.72 |
| Q1 FY26 | ₹1,507 Cr | +12.4% | ₹197 Cr | −2.2% | ₹9.68 |
| Q4 FY25 | ₹1,475 Cr | +15.3% | ₹197 Cr | +3.4% | ₹9.71 |
| Q3 FY25 | ₹1,367 Cr | +13.5% | ₹193 Cr | +2.6% | ₹9.50 |
| Q2 FY25 | ₹1,400 Cr | +7.3% | ₹199 Cr | −12.3% | ₹9.78 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹5,483 Cr | ₹791 Cr |
| FY24 | ₹5,018 Cr | ₹790 Cr |
| FY23 | ₹4,525 Cr | ₹607 Cr |
| FY22 | ₹3,701 Cr | ₹351 Cr |
| FY21 | ₹2,582 Cr | −₹7 Cr |
| FY20 | ₹3,128 Cr | ₹122 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 63.27%
- Foreign institutions: 9.40%
- Domestic institutions: 9.06%
- Non-institutions: 17.65%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [GlaxoSmithKline Pharmaceuticals](https://app.pivotnow.in/stock/GLAXO) | ₹2,455.20 | ₹41,593 Cr | 40.1 | — |
| [Ajanta Pharma](https://app.pivotnow.in/stock/AJANTPHARM) | ₹3,260.00 | ₹40,729 Cr | 38.6 | — |
| [Emcure Pharmaceuticals](https://app.pivotnow.in/stock/EMCURE) | ₹1,759.20 | ₹33,369 Cr | 145.1 | — |
| [Global Health](https://app.pivotnow.in/stock/MEDANTA) | ₹1,215.10 | ₹32,671 Cr | 58.9 | — |
| [Dr. Lal Path Labs](https://app.pivotnow.in/stock/LALPATHLAB) | ₹1,838.50 | ₹30,820 Cr | 58 | — |
| [Wockhardt](https://app.pivotnow.in/stock/WOCKPHARMA) | ₹1,889.60 | ₹30,705 Cr | 144.8 | — |

## Questions and answers

### What is the share price of Narayana Hrudayalaya today?

Narayana Hrudayalaya (NSE: NH) last closed at ₹1,691.90 on 22 Oct 2026. Its 52-week high is ₹2,093.30 and its 52-week low is ₹1,589.00.

### What is the market cap of Narayana Hrudayalaya?

Narayana Hrudayalaya's market capitalisation is ₹34,576 Cr (₹34,576 Cr) at the 22 Oct 2026 close, ranking 244th among the NSE companies Pivot tracks.

### What is the P/E ratio of Narayana Hrudayalaya?

Narayana Hrudayalaya trades at a trailing P/E of 42.4. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 58.9.

### What is the ROE and ROCE of Narayana Hrudayalaya?

Return on equity was 17.8% in FY26 and return on capital employed was 11.9% in FY26 (consolidated figures).

### Is Narayana Hrudayalaya a debt-free company?

No. Narayana Hrudayalaya's debt-to-equity ratio was 1.07 in FY26, with total debt of ₹4,667 Cr.

### What were Narayana Hrudayalaya's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Narayana Hrudayalaya reported revenue of ₹2,684 Cr, +78.0% year on year, and net profit of ₹209 Cr, +6.1% year on year.

### How has Narayana Hrudayalaya stock performed over the last year?

Narayana Hrudayalaya's share price has fallen 2.8% over the past year, −14.2% over three months and −10.8% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Narayana Hrudayalaya?

As of 30 Jun 2026: promoters 63.27%, foreign institutions 9.40%, domestic institutions 9.06%, non-institutions 17.65%.

### Who are Narayana Hrudayalaya's competitors?

The listed Pharma & Healthcare companies closest to Narayana Hrudayalaya by market cap are GlaxoSmithKline Pharmaceuticals, Ajanta Pharma, Emcure Pharmaceuticals, Global Health, Dr. Lal Path Labs and Wockhardt.

### Is Narayana Hrudayalaya a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Narayana Hrudayalaya's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on NH against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.